Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Pavel Marianne) "

Sökning: WFRF:(Pavel Marianne)

  • Resultat 11-20 av 50
  • Föregående 1[2]345Nästa
Sortera/gruppera träfflistan
  • Capdevila, Jaume, et al. (författare)
  • Unmet Medical Needs in Metastatic Lung and Digestive Neuroendocrine Neoplasms
  • 2019
  • Ingår i: Neuroendocrinology. - 0028-3835 .- 1423-0194. ; 108:1, s. 18-25
  • Tidskriftsartikel (refereegranskat)abstract
    • Unmet medical needs are not infrequent in oncology, and these needs are usually of higher magnitude in rare cancers. The field of neuroendocrine neoplasms (NENs) has evolved rapidly during the last decade, and, currently, a new WHO classification is being implemented and several treatment options are available in the metastatic setting after the results of prospective phase III clinical trials. However, several questions are still unanswered, and decisions in our daily clinical practice should be made with limited evidence. In the 2016 meeting of the advisory board of the European Neuroendocrine Tumor Society (ENETS), the main unmet medical needs in the metastatic NENs setting were deeply discussed, and several proposals to try to solve them are presented in this article, including biomarkers, imaging, and therapy.
  • Chazot, Nicolas, et al. (författare)
  • Conserved ancestral tropical niche but different continental histories explain the latitudinal diversity gradient in brush-footed butterflies
  • 2021
  • Ingår i: Nature Communications. - : Nature Publishing Group. - 2041-1723. ; 12:1
  • Tidskriftsartikel (refereegranskat)abstract
    • The global increase in species richness toward the tropics across continents and taxonomic groups, referred to as the latitudinal diversity gradient, stimulated the formulation of many hypotheses to explain the underlying mechanisms of this pattern. We evaluate several of these hypotheses to explain spatial diversity patterns in a butterfly family, the Nymphalidae, by assessing the contributions of speciation, extinction, and dispersal, and also the extent to which these processes differ among regions at the same latitude. We generate a time-calibrated phylogeny containing 2,866 nymphalid species (~45% of extant diversity). Neither speciation nor extinction rate variations consistently explain the latitudinal diversity gradient among regions because temporal diversification dynamics differ greatly across longitude. The Neotropical diversity results from low extinction rates, not high speciation rates, and biotic interchanges with other regions are rare. Southeast Asia is also characterized by a low speciation rate but, unlike the Neotropics, is the main source of dispersal events through time. Our results suggest that global climate change throughout the Cenozoic, combined with tropical niche conservatism, played a major role in generating the modern latitudinal diversity gradient of nymphalid butterflies.
  • Dawod, Mohammed, et al. (författare)
  • Antiproliferative Systemic Therapies for Metastatic Small Bowel Neuroendocrine Tumours
  • 2021
  • Ingår i: Current Treatment Options in Oncology. - 1527-2729 .- 1534-6277. ; 22:8
  • Forskningsöversikt (refereegranskat)abstract
    • Neuroendocrine neoplasms (NENs) are a heterogeneous group of malignancies with rising incidence and prevalence. Outcome and therapy of small bowel neuroendocrine tumours (SBNETs) is variable, depending on the grade, differentiation, tumour burden, as well as the site of the tumour origin. Because of this, multidisciplinary approach is essential. Large randomized clinical trials, with somatostatin analogues (PROMID, CLARINET) or with peptide receptor radionuclide therapy (PRRT) with 177-lutetium (NETTER-1 trial) as well as the mammalian target of rapamycin inhibitor (mTOR) everolimus (RADIANT trials), represent milestones for the medical management of unresectable grade 1 and 2 SBNETS over the last decade. Novel therapies, such as tyrosine kinase inhibitors (TKI), are on the cutting edge. However, multiple unsolved questions remain. This review provides a comprehensive review of the main systemic therapeutic options for advanced SBNETs and discusses the latest guideline recommendations for palliative treatment.
  • Dehasque, Marianne, et al. (författare)
  • Combining Bayesian age models and genetics to investigate population dynamics and extinction of the last mammoths in northern Siberia
  • 2021
  • Ingår i: Quaternary Science Reviews. - 0277-3791 .- 1873-457X. ; 259
  • Tidskriftsartikel (refereegranskat)abstract
    • To understand the causes and implications of an extinction event, detailed information is necessary. However, this can be challenging when working with poorly resolved paleontological data sets. One approach to increase the data resolution is by combining different methods. In this study, we used both radiocarbon and genetic data to reconstruct the population history and extinction dynamics of the woolly mammoth in northern Siberia. We generated 88 new radiocarbon dates and combined these with previously published dates from 626 specimens to construct Bayesian age models. These models show that mammoths disappeared on the eastern Siberian mainland before the onset of the Younger Dryas (12.9–11.7 ky cal BP). Mammoths did however persist in the northernmost parts of central and western Siberia until the early Holocene. Further genetic results of 131 high quality mitogenomes, including 22 new mitogenomes generated in this study, support the hypothesis that mammoths from, or closely related to, a central and/or west- Siberian population recolonized Wrangel Island over the now submerged northern Siberian plains. As mammoths became trapped on the island due to rising sea levels, they lived another ca. 6000 years on Wrangel Island before eventually going extinct ca. 4000 years ago.
  • Dillon, Joseph S., et al. (författare)
  • Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl : Analyses of Phase III Studies in Carcinoid Syndrome
  • 2021
  • Ingår i: Journal of Gastrointestinal Cancer. - 1941-6628 .- 1941-6636. ; 52:1, s. 212-221
  • Tidskriftsartikel (refereegranskat)abstract
    • BackgroundTelotristat ethyl is approved to treat carcinoid syndrome diarrhea in combination with somatostatin analogs. In TELESTAR and TELECAST phase III studies, patients with carcinoid syndrome received telotristat ethyl 250 or 500 mg 3 times per day (tid) or placebo tid in addition to somatostatin analogs. The aim of this prespecified analysis was to examine the time to reductions in bowel movements (BMs) in the TELESTAR and TELECAST studies using survival analysis methods.MethodsFirst occurrence of sustained response was defined as the time to the first day of 2 consecutive weeks with a mean BM frequency improvement of ≥ 30% from baseline during the 12-week double-blind treatment periods. Time to first ≥ 30% worsening in BM frequency was also measured. Treatments were compared with the log-rank test; Cox regression models provided point and confidence interval estimates of the hazard ratios for each trial.ResultsIn TELESTAR and TELECAST, majority of patients (69%) on telotristat ethyl experienced a sustained ≥ 30% improvement in BM frequency. The median time to sustained reduction of at least 30% in BM frequency was significantly faster (fewer days to onset) for telotristat ethyl compared with placebo in both TELESTAR (250 mg, HR = 2.3 [95% CI, 1.3–4.1, P = 0.004]; 500 mg, HR = 2.2 [95% CI, 1.2–3.9, P = 0.009]) and TELECAST (250 mg, HR = 3.9 [95% CI, 1.6–11.1, P = 0.003]; 500 mg, HR = 4.2 [95% CI, 1.7–11.7, P = 0.002]). In TELECAST, 42% of patients on placebo experienced sustained worsening in BM frequency compared with 20% on telotristat ethyl; no significant difference was observed in TELESTAR.ConclusionThe time of onset of sustained BM frequency improvement mean and range are important when considering use of telotristat ethyl in patients with carcinoid syndrome diarrhea. Telotristat ethyl may also reduce sustained worsening in BM frequency.
  • Dromain, Clarisse, et al. (författare)
  • Tumour Growth Rate to predict the outcome of patients with Neuroendocrine Tumours : Performance and sources of variability
  • 2021
  • Ingår i: Neuroendocrinology. - 0028-3835 .- 1423-0194. ; 111:9, s. 831-839
  • Tidskriftsartikel (refereegranskat)abstract
    • INTRODUCTION: Tumor growth rate (TGR), percentage of change in tumor volume/month, has been previously identified as an early radiological biomarker for treatment monitoring in neuroendocrine tumors (NETs) patients. We assessed the performance and reproducibility of TGR 3 months (TGR3m) as a predictor factor of progression-free survival (PFS), including the impact of imaging method and reader variability.METHODS: Baseline and 3-months (±1month) CT/MRI images from patients with advanced, grade 1-2 NETs were retrospectively reviewed by 2 readers. Influence of number of targets, tumor burden and location of lesion on the performance of TGR3m to predict PFS was assessed by uni/multivariable Cox regression analysis. Agreement between readers was assessed by the Lin's concordance coefficient (LCC) and Kappa (KC).RESULTS: A total of 790 lesions were measured in 222 patients. Median PFS was 22.9 months. On univariable analysis, number of lesions (DISCUSSION/CONCLUSION: TGR3m is a robust and early radiological biomarker able to predict PFS. It may be used to identify patients with advanced NETs who require closer radiological follow-up.
  • Garcia-Carbonero, Rocio, et al. (författare)
  • ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms : Systemic Therapy - Chemotherapy
  • 2017
  • Ingår i: Neuroendocrinology. - 0028-3835 .- 1423-0194. ; 105:3, s. 281-294
  • Tidskriftsartikel (refereegranskat)abstract
    • Systemic chemotherapy is indicated in progressive or bulky advanced pancreatic neuroendocrine tumors (NETs) and in grade 3 (G3) neuroendocrine neoplasms (NENs) as per ENETS guidelines. Chemotherapy may be considered in NETs of other sites (lung, thymus, stomach, colon, and rectum) under certain conditions (e.g., when Ki-67 is at a high level [upper G2 range], in rapidly progressive disease and/or after failure of other therapies, or if somatostatin receptor imaging is negative). An ENETS Consensus Conference was held in Antibes (2015) to elaborate guidelines on the standards of care of different diagnostic procedures and therapeutic interventions in NENs. This article provides guidance on chemotherapy including therapeutic indications, dosing schedules, adverse events (including prevention and management), drug interactions, and evaluation of treatment effect for the chemotherapy agents most commonly used in NENs (streptozocin, dacarbazine, fluoropyrimidines, platinum compounds, etoposide, and irinotecan).
  • Holland, Linda Z, et al. (författare)
  • The amphioxus genome illuminates vertebrate origins and cephalochordate biology
  • 2008
  • Ingår i: Genome Research. - 1088-9051 .- 1549-5469. ; 18:7, s. 1100-1111
  • Tidskriftsartikel (refereegranskat)abstract
    • Cephalochordates, urochordates, and vertebrates evolved from a common ancestor over 520 million years ago. To improve our understanding of chordate evolution and the origin of vertebrates, we intensively searched for particular genes, gene families, and conserved noncoding elements in the sequenced genome of the cephalochordate Branchiostoma floridae, commonly called amphioxus or lancelets. Special attention was given to homeobox genes, opsin genes, genes involved in neural crest development, nuclear receptor genes, genes encoding components of the endocrine and immune systems, and conserved cis-regulatory enhancers. The amphioxus genome contains a basic set of chordate genes involved in development and cell signaling, including a fifteenth Hox gene. This set includes many genes that were co-opted in vertebrates for new roles in neural crest development and adaptive immunity. However, where amphioxus has a single gene, vertebrates often have two, three, or four paralogs derived from two whole-genome duplication events. In addition, several transcriptional enhancers are conserved between amphioxus and vertebrates--a very wide phylogenetic distance. In contrast, urochordate genomes have lost many genes, including a diversity of homeobox families and genes involved in steroid hormone function. The amphioxus genome also exhibits derived features, including duplications of opsins and genes proposed to function in innate immunity and endocrine systems. Our results indicate that the amphioxus genome is elemental to an understanding of the biology and evolution of nonchordate deuterostomes, invertebrate chordates, and vertebrates.
Skapa referenser, mejla, bekava och länka
  • Resultat 11-20 av 50
  • Föregående 1[2]345Nästa
Typ av publikation
tidskriftsartikel (45)
forskningsöversikt (5)
Typ av innehåll
refereegranskat (39)
övrigt vetenskapligt (11)
Pavel, Marianne (33)
Öberg, Kjell (13)
Kulke, Matthew H. (12)
Pavel, Marianne E (11)
Öberg, Kjell, 1946- (11)
Lapuerta, Pablo (11)
visa fler...
Bergsland, Emily (10)
Yao, James C. (10)
Caplin, Martyn (9)
Welin, Staffan (8)
Anthony, Lowell B. (8)
Valle, Juan W. (8)
Van Cutsem, Eric (7)
Baudin, Eric (7)
Hoersch, Dieter (7)
Hörsch, Dieter (7)
Jackson, Shanna (6)
Hainsworth, John D. (6)
Warner, Richard R. P ... (6)
Crona, Joakim (5)
Kaltsas, Gregory (5)
Capdevila, Jaume (5)
Sundin, Anders, 1954 ... (5)
Caplin, Martyn E. (5)
Lamarca, Angela (5)
Öberg, Kjell E (4)
Bodei, Lisa (4)
Metz, David C. (4)
Dromain, Clarisse (4)
Falconi, Massimo (4)
Strosberg, Jonathan (4)
Anthony, Lowell (4)
Warner, Richard (4)
Kunz, Pamela (4)
O'Dorisio, Thomas M. (4)
Dillon, Joseph S. (4)
Costa, Frederico (4)
Salazar, Ramon (4)
Bajetta, Emilio (4)
Krenning, Eric (4)
McNicol, Anne M (3)
Ruszniewski, Philipp ... (3)
Eriksson, Barbro (3)
de Herder, Wouter W (3)
O'Toole, Dermot (3)
Bakker, Bert (3)
Falkerby, Jenny (3)
Modlin, Irvin M (3)
Díez-del-Molino, Dav ... (3)
Gorbounova, Vera (3)
visa färre...
Uppsala universitet (43)
Lunds universitet (4)
Göteborgs universitet (2)
Stockholms universitet (2)
Kungliga Tekniska Högskolan (1)
Mittuniversitetet (1)
visa fler...
Karolinska Institutet (1)
visa färre...
Engelska (50)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (37)
Naturvetenskap (3)
Teknik (1)
Samhällsvetenskap (1)


Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy